510(k) for Genzyme Diagnostics:
This article was originally published in Clinica
Genzyme Diagnostics has received FDA 510(k) clearance to market its GlyPro assay for monitoring blood glucose levels in diabetic patients. By measuring the level of glycated serum proteins, commonly known as fructosamine, the test presents doctors with a representative measurement of the average blood glucose levels from the previous two to three weeks. This offers a cost-effective way of measuring glucose control over time, said the Cambridge, Massachusetts-based company.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.